TUSTIN, Calif., Nov. 6 /PRNewswire-FirstCall/ -- (http://www.amdl.com)
AMDL, Inc. (Amex: ADL), a leading vertically-integrated pharmaceutical
company with major operations in China and the U.S., today announced its
newly appointed Chairman and CEO Mr. Douglas MacLellan will present at
Rodman & Renshaw's Annual Global Investment Conference taking place on
Wednesday, November 12th, 2008 at the New York Palace Hotel in New York
City.

Mr. MacLellan will provide an informative overview of AMDL's core
business and growth strategy for its China specialty pharmaceuticals,
in-vitro diagnostics and cancer therapeutic divisions. The Company has an
aggressive and focused approach to capitalize on these three market
sectors, positioning AMDL as one of most rapidly growing and
highly-opportunistic micro-cap investment prospects in the
vertically-integrated, specialty pharmaceutical sector.

In 2008 alone, AMDL met numerous operational milestones which include:
securing more than $25 million in sales contracts for its best-selling HPE
anti-aging product line; expanding AMDL's overall revenue opportunity for
HPE by launching additional HPE product formulations; and successfully
securing US FDA clearance for AMDL's ELISA DR-70(R) FDP cancer diagnostic
test. The ELISA DR-70(R) FDP cancer diagnostic test is the first test to be
cleared by the US FDA in over 25 years for the monitoring of colorectal
cancer.

Attendees wishing to learn more about the Company can attend Mr.
MacLellan's presentation which is scheduled at 9:55 a.m. EST in the Henry
Salon, 5th Floor of the New York Palace Hotel. Additionally, interested
investors can visit the Company's corporate website at http://www.amdl.com
or contact AMDL's investor relations department at 206.310.5323.

About AMDL:

Headquartered in Tustin, CA with operations in Shenzhen, Jiangxi, and
Jilin, China, AMDL, Inc., along with its subsidiary Jade Pharmaceutical
Inc. (JPI), is a vertically integrated bio-pharmaceutical company devoted
to the research, development, manufacturing, and marketing of diagnostic,
pharmaceutical, nutritional supplement, and cosmetic products. The company
employs over 400 people in the U.S. and China. The Company has an
additional 4 pharmaceutical and diagnostic products under review by various
regulatory authorities.

Forward Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform
Act of 1995: The statements contained in this document include certain
predictions and projections that may be considered forward-looking
statements under securities law. These statements involve a number of
important risks and uncertainties that could cause actual results to differ
materially including, but not limited to, the performance of joint venture
partners, as well as other economic, competitive and technological factors
involving the Company's operations, markets, services, products, and
prices. With respect to AMDL, Inc., except for the historical information
contained herein, the matters discussed in this document are
forward-looking statements involving risks and uncertainties that could
cause actual results to differ materially from those in such
forward-looking statements. Potential risks and uncertainties related to
the Company's access to additional capital, competition and dependence on
key management.

(Date:10/12/2017)... ... October 12, 2017 , ... ... announced today that they have entered into a multiyear collaboration to identify and ... researchers with additional tools for gene editing across all applications. , Under the ...

(Date:10/12/2017)... ... October 12, 2017 , ... ... genomics analysis platform specifically designed for life science researchers to analyze and ... researcher Rosalind Franklin, who made a major contribution to the discovery of ...